nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Temozolomide—malignant glioma	0.147	1	CbGbCtD
Lurasidone—HTR2A—choroid plexus—malignant glioma	0.051	0.113	CbGeAlD
Lurasidone—HTR7—pons—malignant glioma	0.0291	0.0642	CbGeAlD
Lurasidone—HTR2A—cerebellar cortex—malignant glioma	0.0257	0.0567	CbGeAlD
Lurasidone—HTR1A—telencephalic ventricle—malignant glioma	0.0251	0.0553	CbGeAlD
Lurasidone—HTR7—telencephalic ventricle—malignant glioma	0.024	0.0529	CbGeAlD
Lurasidone—DRD2—telencephalic ventricle—malignant glioma	0.0227	0.05	CbGeAlD
Lurasidone—HTR2A—pons—malignant glioma	0.0182	0.0401	CbGeAlD
Lurasidone—HTR2A—vertebral column—malignant glioma	0.018	0.0398	CbGeAlD
Lurasidone—HTR2A—telencephalic ventricle—malignant glioma	0.0149	0.033	CbGeAlD
Lurasidone—HTR2A—pineal body—malignant glioma	0.013	0.0286	CbGeAlD
Lurasidone—HTR7—endothelium—malignant glioma	0.0129	0.0284	CbGeAlD
Lurasidone—HTR7—blood vessel—malignant glioma	0.0119	0.0262	CbGeAlD
Lurasidone—Deep vein thrombosis—Temozolomide—malignant glioma	0.00964	0.0316	CcSEcCtD
Lurasidone—Hypokinesia—Carmustine—malignant glioma	0.00899	0.0294	CcSEcCtD
Lurasidone—HTR2A—endothelium—malignant glioma	0.00802	0.0177	CbGeAlD
Lurasidone—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00779	0.0255	CcSEcCtD
Lurasidone—HTR2A—blood vessel—malignant glioma	0.0074	0.0163	CbGeAlD
Lurasidone—HTR1A—brainstem—malignant glioma	0.00679	0.015	CbGeAlD
Lurasidone—Breast pain—Temozolomide—malignant glioma	0.00672	0.022	CcSEcCtD
Lurasidone—Amenorrhoea—Temozolomide—malignant glioma	0.00668	0.0219	CcSEcCtD
Lurasidone—HTR7—brainstem—malignant glioma	0.00649	0.0143	CbGeAlD
Lurasidone—Gait disturbance—Carmustine—malignant glioma	0.00622	0.0204	CcSEcCtD
Lurasidone—Neck pain—Carmustine—malignant glioma	0.00614	0.0201	CcSEcCtD
Lurasidone—DRD2—brainstem—malignant glioma	0.00613	0.0135	CbGeAlD
Lurasidone—Pulmonary embolism—Carmustine—malignant glioma	0.00607	0.0199	CcSEcCtD
Lurasidone—HTR1A—telencephalon—malignant glioma	0.00602	0.0133	CbGeAlD
Lurasidone—Gait disturbance—Temozolomide—malignant glioma	0.00601	0.0197	CcSEcCtD
Lurasidone—DRD2—retina—malignant glioma	0.00592	0.013	CbGeAlD
Lurasidone—Pulmonary embolism—Temozolomide—malignant glioma	0.00587	0.0192	CcSEcCtD
Lurasidone—HTR7—telencephalon—malignant glioma	0.00576	0.0127	CbGeAlD
Lurasidone—DRD2—telencephalon—malignant glioma	0.00544	0.012	CbGeAlD
Lurasidone—ADRA2C—telencephalon—malignant glioma	0.00529	0.0117	CbGeAlD
Lurasidone—Diabetes mellitus—Carmustine—malignant glioma	0.00507	0.0166	CcSEcCtD
Lurasidone—Hot flush—Temozolomide—malignant glioma	0.00455	0.0149	CcSEcCtD
Lurasidone—HTR7—medulla oblongata—malignant glioma	0.00452	0.00997	CbGeAlD
Lurasidone—Menopausal symptoms—Temozolomide—malignant glioma	0.00451	0.0148	CcSEcCtD
Lurasidone—HTR2A—embryo—malignant glioma	0.00441	0.00973	CbGeAlD
Lurasidone—HTR1A—midbrain—malignant glioma	0.00432	0.00954	CbGeAlD
Lurasidone—ADRA2A—telencephalon—malignant glioma	0.00422	0.00931	CbGeAlD
Lurasidone—HTR1A—spinal cord—malignant glioma	0.00422	0.00931	CbGeAlD
Lurasidone—ADRA2C—medulla oblongata—malignant glioma	0.00416	0.00917	CbGeAlD
Lurasidone—HTR7—midbrain—malignant glioma	0.00413	0.00912	CbGeAlD
Lurasidone—HTR2A—brainstem—malignant glioma	0.00404	0.00892	CbGeAlD
Lurasidone—HTR7—spinal cord—malignant glioma	0.00403	0.00889	CbGeAlD
Lurasidone—DRD2—midbrain—malignant glioma	0.00391	0.00862	CbGeAlD
Lurasidone—HTR2A—retina—malignant glioma	0.0039	0.0086	CbGeAlD
Lurasidone—Breast disorder—Temozolomide—malignant glioma	0.00385	0.0126	CcSEcCtD
Lurasidone—Dysphagia—Carmustine—malignant glioma	0.00381	0.0125	CcSEcCtD
Lurasidone—ADRA2C—midbrain—malignant glioma	0.0038	0.00838	CbGeAlD
Lurasidone—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00376	0.0123	CcSEcCtD
Lurasidone—ADRA2C—spinal cord—malignant glioma	0.00371	0.00817	CbGeAlD
Lurasidone—Dysphagia—Temozolomide—malignant glioma	0.00368	0.012	CcSEcCtD
Lurasidone—HTR2A—telencephalon—malignant glioma	0.00359	0.00792	CbGeAlD
Lurasidone—Neutropenia—Carmustine—malignant glioma	0.00356	0.0117	CcSEcCtD
Lurasidone—Neutropenia—Temozolomide—malignant glioma	0.00344	0.0113	CcSEcCtD
Lurasidone—Dysuria—Temozolomide—malignant glioma	0.00344	0.0113	CcSEcCtD
Lurasidone—Hyperglycaemia—Carmustine—malignant glioma	0.00344	0.0112	CcSEcCtD
Lurasidone—HTR1A—central nervous system—malignant glioma	0.00342	0.00755	CbGeAlD
Lurasidone—Erectile dysfunction—Temozolomide—malignant glioma	0.00339	0.0111	CcSEcCtD
Lurasidone—Weight increased—Temozolomide—malignant glioma	0.00335	0.011	CcSEcCtD
Lurasidone—HTR1A—cerebellum—malignant glioma	0.00335	0.00738	CbGeAlD
Lurasidone—Renal failure—Carmustine—malignant glioma	0.00334	0.0109	CcSEcCtD
Lurasidone—Hyperglycaemia—Temozolomide—malignant glioma	0.00332	0.0109	CcSEcCtD
Lurasidone—ADRA2A—medulla oblongata—malignant glioma	0.00332	0.00731	CbGeAlD
Lurasidone—Urinary tract infection—Carmustine—malignant glioma	0.0033	0.0108	CcSEcCtD
Lurasidone—Infestation—Temozolomide—malignant glioma	0.00328	0.0107	CcSEcCtD
Lurasidone—Infestation NOS—Temozolomide—malignant glioma	0.00328	0.0107	CcSEcCtD
Lurasidone—HTR7—central nervous system—malignant glioma	0.00327	0.00721	CbGeAlD
Lurasidone—HTR7—cerebellum—malignant glioma	0.0032	0.00705	CbGeAlD
Lurasidone—Urinary tract infection—Temozolomide—malignant glioma	0.00319	0.0104	CcSEcCtD
Lurasidone—Hepatobiliary disease—Temozolomide—malignant glioma	0.0031	0.0102	CcSEcCtD
Lurasidone—DRD2—central nervous system—malignant glioma	0.00309	0.00682	CbGeAlD
Lurasidone—ADRA2A—midbrain—malignant glioma	0.00303	0.00669	CbGeAlD
Lurasidone—DRD2—cerebellum—malignant glioma	0.00302	0.00667	CbGeAlD
Lurasidone—ADRA2C—central nervous system—malignant glioma	0.00301	0.00663	CbGeAlD
Lurasidone—Connective tissue disorder—Carmustine—malignant glioma	0.003	0.00981	CcSEcCtD
Lurasidone—ADRA2A—spinal cord—malignant glioma	0.00296	0.00652	CbGeAlD
Lurasidone—ADRA2C—cerebellum—malignant glioma	0.00294	0.00648	CbGeAlD
Lurasidone—Urinary tract disorder—Temozolomide—malignant glioma	0.00291	0.00952	CcSEcCtD
Lurasidone—Connective tissue disorder—Temozolomide—malignant glioma	0.0029	0.00948	CcSEcCtD
Lurasidone—Urethral disorder—Temozolomide—malignant glioma	0.00289	0.00945	CcSEcCtD
Lurasidone—Eye disorder—Carmustine—malignant glioma	0.00285	0.00932	CcSEcCtD
Lurasidone—HTR2A—medulla oblongata—malignant glioma	0.00282	0.00622	CbGeAlD
Lurasidone—Eye disorder—Temozolomide—malignant glioma	0.00275	0.00901	CcSEcCtD
Lurasidone—Cardiac disorder—Temozolomide—malignant glioma	0.00273	0.00895	CcSEcCtD
Lurasidone—Arrhythmia—Carmustine—malignant glioma	0.00272	0.00891	CcSEcCtD
Lurasidone—HTR1A—brain—malignant glioma	0.00272	0.00599	CbGeAlD
Lurasidone—Angiopathy—Temozolomide—malignant glioma	0.00267	0.00875	CcSEcCtD
Lurasidone—Mental disorder—Carmustine—malignant glioma	0.00267	0.00874	CcSEcCtD
Lurasidone—Malnutrition—Carmustine—malignant glioma	0.00265	0.00869	CcSEcCtD
Lurasidone—HTR7—brain—malignant glioma	0.0026	0.00573	CbGeAlD
Lurasidone—Mental disorder—Temozolomide—malignant glioma	0.00258	0.00845	CcSEcCtD
Lurasidone—HTR2A—midbrain—malignant glioma	0.00258	0.00568	CbGeAlD
Lurasidone—Back pain—Carmustine—malignant glioma	0.00257	0.0084	CcSEcCtD
Lurasidone—Malnutrition—Temozolomide—malignant glioma	0.00256	0.00839	CcSEcCtD
Lurasidone—HTR2A—spinal cord—malignant glioma	0.00251	0.00555	CbGeAlD
Lurasidone—Vision blurred—Carmustine—malignant glioma	0.0025	0.00819	CcSEcCtD
Lurasidone—Tremor—Carmustine—malignant glioma	0.00249	0.00814	CcSEcCtD
Lurasidone—Back pain—Temozolomide—malignant glioma	0.00248	0.00812	CcSEcCtD
Lurasidone—DRD2—brain—malignant glioma	0.00246	0.00542	CbGeAlD
Lurasidone—Anaemia—Carmustine—malignant glioma	0.00245	0.00803	CcSEcCtD
Lurasidone—Agitation—Carmustine—malignant glioma	0.00244	0.00798	CcSEcCtD
Lurasidone—Vision blurred—Temozolomide—malignant glioma	0.00242	0.00791	CcSEcCtD
Lurasidone—Tremor—Temozolomide—malignant glioma	0.0024	0.00786	CcSEcCtD
Lurasidone—ADRA2A—central nervous system—malignant glioma	0.0024	0.00529	CbGeAlD
Lurasidone—ADRA2C—brain—malignant glioma	0.00239	0.00526	CbGeAlD
Lurasidone—Leukopenia—Carmustine—malignant glioma	0.00238	0.00777	CcSEcCtD
Lurasidone—Anaemia—Temozolomide—malignant glioma	0.00237	0.00776	CcSEcCtD
Lurasidone—Agitation—Temozolomide—malignant glioma	0.00236	0.00771	CcSEcCtD
Lurasidone—ADRA2A—cerebellum—malignant glioma	0.00235	0.00517	CbGeAlD
Lurasidone—Angioedema—Temozolomide—malignant glioma	0.00234	0.00767	CcSEcCtD
Lurasidone—Malaise—Temozolomide—malignant glioma	0.00231	0.00757	CcSEcCtD
Lurasidone—Vertigo—Temozolomide—malignant glioma	0.0023	0.00754	CcSEcCtD
Lurasidone—Convulsion—Carmustine—malignant glioma	0.0023	0.00753	CcSEcCtD
Lurasidone—Leukopenia—Temozolomide—malignant glioma	0.0023	0.00751	CcSEcCtD
Lurasidone—Hypertension—Carmustine—malignant glioma	0.00229	0.0075	CcSEcCtD
Lurasidone—Myalgia—Carmustine—malignant glioma	0.00226	0.00739	CcSEcCtD
Lurasidone—Anxiety—Carmustine—malignant glioma	0.00225	0.00737	CcSEcCtD
Lurasidone—Convulsion—Temozolomide—malignant glioma	0.00222	0.00727	CcSEcCtD
Lurasidone—Hypertension—Temozolomide—malignant glioma	0.00221	0.00725	CcSEcCtD
Lurasidone—Myalgia—Temozolomide—malignant glioma	0.00218	0.00715	CcSEcCtD
Lurasidone—Anxiety—Temozolomide—malignant glioma	0.00218	0.00712	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00217	0.0071	CcSEcCtD
Lurasidone—Infection—Carmustine—malignant glioma	0.00215	0.00704	CcSEcCtD
Lurasidone—Dry mouth—Temozolomide—malignant glioma	0.00214	0.00699	CcSEcCtD
Lurasidone—Tachycardia—Carmustine—malignant glioma	0.00211	0.00692	CcSEcCtD
Lurasidone—Infection—Temozolomide—malignant glioma	0.00208	0.00681	CcSEcCtD
Lurasidone—Nervous system disorder—Temozolomide—malignant glioma	0.00205	0.00672	CcSEcCtD
Lurasidone—HTR2A—central nervous system—malignant glioma	0.00204	0.0045	CbGeAlD
Lurasidone—Skin disorder—Temozolomide—malignant glioma	0.00203	0.00665	CcSEcCtD
Lurasidone—Hypotension—Carmustine—malignant glioma	0.00202	0.00662	CcSEcCtD
Lurasidone—Hyperhidrosis—Temozolomide—malignant glioma	0.00202	0.00662	CcSEcCtD
Lurasidone—HTR2A—cerebellum—malignant glioma	0.00199	0.0044	CbGeAlD
Lurasidone—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00197	0.00646	CcSEcCtD
Lurasidone—Insomnia—Carmustine—malignant glioma	0.00196	0.00641	CcSEcCtD
Lurasidone—Dyspnoea—Carmustine—malignant glioma	0.00193	0.00632	CcSEcCtD
Lurasidone—Somnolence—Carmustine—malignant glioma	0.00193	0.0063	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00191	0.00624	CcSEcCtD
Lurasidone—ADRA2A—brain—malignant glioma	0.0019	0.0042	CbGeAlD
Lurasidone—Insomnia—Temozolomide—malignant glioma	0.00189	0.0062	CcSEcCtD
Lurasidone—CYP3A4—central nervous system—malignant glioma	0.00189	0.00416	CbGeAlD
Lurasidone—Decreased appetite—Carmustine—malignant glioma	0.00188	0.00616	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Carmustine—malignant glioma	0.00187	0.00612	CcSEcCtD
Lurasidone—Dyspnoea—Temozolomide—malignant glioma	0.00187	0.00611	CcSEcCtD
Lurasidone—Somnolence—Temozolomide—malignant glioma	0.00186	0.00609	CcSEcCtD
Lurasidone—Dyspepsia—Temozolomide—malignant glioma	0.00184	0.00603	CcSEcCtD
Lurasidone—Decreased appetite—Temozolomide—malignant glioma	0.00182	0.00596	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00181	0.00591	CcSEcCtD
Lurasidone—Fatigue—Temozolomide—malignant glioma	0.0018	0.00591	CcSEcCtD
Lurasidone—Gastrointestinal pain—Carmustine—malignant glioma	0.00177	0.0058	CcSEcCtD
Lurasidone—Abdominal pain—Carmustine—malignant glioma	0.00171	0.0056	CcSEcCtD
Lurasidone—Gastrointestinal pain—Temozolomide—malignant glioma	0.00171	0.0056	CcSEcCtD
Lurasidone—Abdominal pain—Temozolomide—malignant glioma	0.00165	0.00542	CcSEcCtD
Lurasidone—HTR2A—brain—malignant glioma	0.00162	0.00357	CbGeAlD
Lurasidone—Asthenia—Carmustine—malignant glioma	0.00155	0.00509	CcSEcCtD
Lurasidone—Asthenia—Temozolomide—malignant glioma	0.0015	0.00492	CcSEcCtD
Lurasidone—Diarrhoea—Carmustine—malignant glioma	0.00148	0.00485	CcSEcCtD
Lurasidone—Pruritus—Temozolomide—malignant glioma	0.00148	0.00485	CcSEcCtD
Lurasidone—Dizziness—Carmustine—malignant glioma	0.00143	0.00469	CcSEcCtD
Lurasidone—Diarrhoea—Temozolomide—malignant glioma	0.00143	0.00469	CcSEcCtD
Lurasidone—Dizziness—Temozolomide—malignant glioma	0.00138	0.00453	CcSEcCtD
Lurasidone—Vomiting—Carmustine—malignant glioma	0.00138	0.00451	CcSEcCtD
Lurasidone—Rash—Carmustine—malignant glioma	0.00137	0.00447	CcSEcCtD
Lurasidone—Dermatitis—Carmustine—malignant glioma	0.00136	0.00447	CcSEcCtD
Lurasidone—Vomiting—Temozolomide—malignant glioma	0.00133	0.00436	CcSEcCtD
Lurasidone—Rash—Temozolomide—malignant glioma	0.00132	0.00432	CcSEcCtD
Lurasidone—Dermatitis—Temozolomide—malignant glioma	0.00132	0.00432	CcSEcCtD
Lurasidone—Nausea—Carmustine—malignant glioma	0.00129	0.00421	CcSEcCtD
Lurasidone—Nausea—Temozolomide—malignant glioma	0.00124	0.00407	CcSEcCtD
Lurasidone—HTR7—Signaling Pathways—PIK3CB—malignant glioma	2.66e-05	0.000283	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—BAD—malignant glioma	2.65e-05	0.000283	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CAV1—malignant glioma	2.65e-05	0.000282	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—IL2—malignant glioma	2.65e-05	0.000282	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL2—malignant glioma	2.64e-05	0.000282	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TERT—malignant glioma	2.63e-05	0.000281	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOTCH1—malignant glioma	2.63e-05	0.00028	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CB—malignant glioma	2.62e-05	0.000279	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CD—malignant glioma	2.61e-05	0.000278	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PDGFB—malignant glioma	2.61e-05	0.000278	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PDGFRA—malignant glioma	2.6e-05	0.000277	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FGFR1—malignant glioma	2.6e-05	0.000277	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—FN1—malignant glioma	2.6e-05	0.000277	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—F2—malignant glioma	2.6e-05	0.000277	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CD80—malignant glioma	2.57e-05	0.000274	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PDGFB—malignant glioma	2.57e-05	0.000274	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APC—malignant glioma	2.57e-05	0.000274	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CG—malignant glioma	2.57e-05	0.000274	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—BAD—malignant glioma	2.57e-05	0.000273	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HIF1A—malignant glioma	2.56e-05	0.000273	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FGFR1—malignant glioma	2.56e-05	0.000272	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCL8—malignant glioma	2.55e-05	0.000272	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOTCH1—malignant glioma	2.54e-05	0.000271	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGF—malignant glioma	2.54e-05	0.000271	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SPP1—malignant glioma	2.53e-05	0.000269	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTPN11—malignant glioma	2.52e-05	0.000269	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HIF1A—malignant glioma	2.52e-05	0.000268	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCL8—malignant glioma	2.52e-05	0.000268	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CD80—malignant glioma	2.49e-05	0.000265	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CG—malignant glioma	2.48e-05	0.000265	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APC—malignant glioma	2.48e-05	0.000265	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CAV1—malignant glioma	2.48e-05	0.000264	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—AKT1—malignant glioma	2.46e-05	0.000263	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGF—malignant glioma	2.46e-05	0.000262	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KDR—malignant glioma	2.45e-05	0.000261	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CASP3—malignant glioma	2.44e-05	0.00026	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTPN11—malignant glioma	2.44e-05	0.00026	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL2—malignant glioma	2.44e-05	0.00026	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CAV1—malignant glioma	2.44e-05	0.00026	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—BRAF—malignant glioma	2.41e-05	0.000257	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CG—malignant glioma	2.41e-05	0.000257	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KDR—malignant glioma	2.41e-05	0.000257	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL2—malignant glioma	2.4e-05	0.000256	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TERT—malignant glioma	2.4e-05	0.000255	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—F2—malignant glioma	2.36e-05	0.000251	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FN1—malignant glioma	2.36e-05	0.000251	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT2—malignant glioma	2.35e-05	0.00025	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—EGFR—malignant glioma	2.34e-05	0.000249	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PDGFB—malignant glioma	2.34e-05	0.000249	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—BRAF—malignant glioma	2.34e-05	0.000249	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARG—malignant glioma	2.33e-05	0.000248	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—BAD—malignant glioma	2.33e-05	0.000248	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FGFR1—malignant glioma	2.33e-05	0.000248	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—F2—malignant glioma	2.32e-05	0.000247	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FN1—malignant glioma	2.32e-05	0.000247	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MMP9—malignant glioma	2.31e-05	0.000246	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOTCH1—malignant glioma	2.31e-05	0.000246	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PTEN—malignant glioma	2.29e-05	0.000245	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HIF1A—malignant glioma	2.29e-05	0.000244	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—BAD—malignant glioma	2.29e-05	0.000244	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CB—malignant glioma	2.28e-05	0.000243	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT2—malignant glioma	2.27e-05	0.000242	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—AKT1—malignant glioma	2.27e-05	0.000242	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOTCH1—malignant glioma	2.27e-05	0.000242	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—EGFR—malignant glioma	2.26e-05	0.000241	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CD80—malignant glioma	2.26e-05	0.000241	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CD—malignant glioma	2.26e-05	0.000241	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTGS2—malignant glioma	2.26e-05	0.00024	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APC—malignant glioma	2.25e-05	0.00024	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CG—malignant glioma	2.25e-05	0.00024	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—AKT1—malignant glioma	2.24e-05	0.000239	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—PIK3CA—malignant glioma	2.24e-05	0.000238	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGF—malignant glioma	2.23e-05	0.000238	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CD80—malignant glioma	2.22e-05	0.000237	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APC—malignant glioma	2.22e-05	0.000236	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CG—malignant glioma	2.22e-05	0.000236	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CAV1—malignant glioma	2.22e-05	0.000236	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTPN11—malignant glioma	2.21e-05	0.000236	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—KRAS—malignant glioma	2.21e-05	0.000236	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGF—malignant glioma	2.19e-05	0.000234	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KDR—malignant glioma	2.19e-05	0.000233	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CD—malignant glioma	2.18e-05	0.000233	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTPN11—malignant glioma	2.18e-05	0.000232	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTT1—malignant glioma	2.17e-05	0.000232	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PIK3CA—malignant glioma	2.16e-05	0.000231	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—FGF2—malignant glioma	2.16e-05	0.00023	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—malignant glioma	2.14e-05	0.000228	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CD—malignant glioma	2.12e-05	0.000226	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—BRAF—malignant glioma	2.12e-05	0.000226	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FN1—malignant glioma	2.11e-05	0.000225	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—F2—malignant glioma	2.11e-05	0.000225	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—FGF2—malignant glioma	2.09e-05	0.000223	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—BRAF—malignant glioma	2.09e-05	0.000222	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BAD—malignant glioma	2.08e-05	0.000222	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—malignant glioma	2.07e-05	0.000221	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOTCH1—malignant glioma	2.06e-05	0.00022	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT2—malignant glioma	2.06e-05	0.00022	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—malignant glioma	2.05e-05	0.000219	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—malignant glioma	2.05e-05	0.000219	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS1—malignant glioma	2.04e-05	0.000217	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—malignant glioma	2.03e-05	0.000216	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT2—malignant glioma	2.03e-05	0.000216	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MDM2—malignant glioma	2.02e-05	0.000216	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CD80—malignant glioma	2.02e-05	0.000215	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—malignant glioma	2.02e-05	0.000215	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APC—malignant glioma	2.02e-05	0.000215	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—malignant glioma	2.02e-05	0.000215	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—RAF1—malignant glioma	2.02e-05	0.000215	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGF—malignant glioma	1.99e-05	0.000213	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—malignant glioma	1.99e-05	0.000212	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTPN11—malignant glioma	1.98e-05	0.000211	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—malignant glioma	1.98e-05	0.000211	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—malignant glioma	1.97e-05	0.00021	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—malignant glioma	1.97e-05	0.00021	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—malignant glioma	1.96e-05	0.000209	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—malignant glioma	1.96e-05	0.000209	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MDM2—malignant glioma	1.96e-05	0.000209	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	1.95e-05	0.000208	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—RAF1—malignant glioma	1.95e-05	0.000208	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—malignant glioma	1.94e-05	0.000207	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	1.93e-05	0.000206	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—malignant glioma	1.93e-05	0.000206	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—malignant glioma	1.91e-05	0.000203	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—malignant glioma	1.91e-05	0.000203	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—malignant glioma	1.9e-05	0.000203	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FGF2—malignant glioma	1.9e-05	0.000202	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BRAF—malignant glioma	1.9e-05	0.000202	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—BCHE—malignant glioma	1.89e-05	0.000202	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—malignant glioma	1.89e-05	0.000202	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.87e-05	0.000199	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FGF2—malignant glioma	1.87e-05	0.000199	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—malignant glioma	1.86e-05	0.000199	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—malignant glioma	1.85e-05	0.000197	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT2—malignant glioma	1.85e-05	0.000197	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	1.84e-05	0.000196	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—malignant glioma	1.83e-05	0.000195	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—malignant glioma	1.83e-05	0.000195	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—malignant glioma	1.83e-05	0.000195	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—malignant glioma	1.81e-05	0.000193	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—malignant glioma	1.81e-05	0.000193	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—malignant glioma	1.78e-05	0.00019	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MDM2—malignant glioma	1.78e-05	0.000189	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	1.77e-05	0.000189	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RAF1—malignant glioma	1.77e-05	0.000189	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—malignant glioma	1.77e-05	0.000188	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—malignant glioma	1.76e-05	0.000188	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	1.76e-05	0.000187	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	1.75e-05	0.000187	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—malignant glioma	1.75e-05	0.000187	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—malignant glioma	1.75e-05	0.000187	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—malignant glioma	1.75e-05	0.000186	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MDM2—malignant glioma	1.75e-05	0.000186	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RAF1—malignant glioma	1.74e-05	0.000186	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	1.74e-05	0.000185	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—malignant glioma	1.73e-05	0.000184	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—malignant glioma	1.72e-05	0.000184	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—malignant glioma	1.71e-05	0.000182	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—malignant glioma	1.7e-05	0.000181	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	1.7e-05	0.000181	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FGF2—malignant glioma	1.7e-05	0.000181	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—malignant glioma	1.66e-05	0.000177	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—malignant glioma	1.66e-05	0.000177	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—malignant glioma	1.65e-05	0.000176	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—malignant glioma	1.65e-05	0.000175	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—malignant glioma	1.63e-05	0.000174	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—malignant glioma	1.62e-05	0.000172	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—malignant glioma	1.6e-05	0.000171	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—malignant glioma	1.6e-05	0.000171	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—malignant glioma	1.6e-05	0.00017	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	1.6e-05	0.00017	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MDM2—malignant glioma	1.59e-05	0.000169	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—malignant glioma	1.59e-05	0.000169	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—malignant glioma	1.59e-05	0.000169	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RAF1—malignant glioma	1.58e-05	0.000169	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	1.58e-05	0.000168	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	1.57e-05	0.000167	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—malignant glioma	1.57e-05	0.000167	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—malignant glioma	1.56e-05	0.000167	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—malignant glioma	1.56e-05	0.000166	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	1.55e-05	0.000165	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—malignant glioma	1.54e-05	0.000164	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—malignant glioma	1.52e-05	0.000162	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—malignant glioma	1.51e-05	0.000161	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—malignant glioma	1.5e-05	0.00016	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—malignant glioma	1.49e-05	0.000159	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	1.49e-05	0.000158	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—malignant glioma	1.49e-05	0.000158	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—malignant glioma	1.48e-05	0.000157	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—malignant glioma	1.47e-05	0.000157	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—malignant glioma	1.47e-05	0.000157	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CAT—malignant glioma	1.47e-05	0.000156	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—malignant glioma	1.46e-05	0.000155	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	1.44e-05	0.000153	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—malignant glioma	1.43e-05	0.000153	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—malignant glioma	1.42e-05	0.000152	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—malignant glioma	1.42e-05	0.000151	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—malignant glioma	1.41e-05	0.000151	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—malignant glioma	1.39e-05	0.000148	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOR1—malignant glioma	1.38e-05	0.000148	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—malignant glioma	1.38e-05	0.000147	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—malignant glioma	1.37e-05	0.000146	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—malignant glioma	1.35e-05	0.000144	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—malignant glioma	1.34e-05	0.000143	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—malignant glioma	1.34e-05	0.000143	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—malignant glioma	1.34e-05	0.000142	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—malignant glioma	1.34e-05	0.000142	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—malignant glioma	1.33e-05	0.000141	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—malignant glioma	1.32e-05	0.000141	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—malignant glioma	1.31e-05	0.00014	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—malignant glioma	1.31e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	1.3e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—malignant glioma	1.26e-05	0.000135	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—malignant glioma	1.24e-05	0.000132	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—malignant glioma	1.22e-05	0.00013	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—malignant glioma	1.21e-05	0.000129	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	1.21e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	1.2e-05	0.000128	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—malignant glioma	1.2e-05	0.000127	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—malignant glioma	1.19e-05	0.000127	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—malignant glioma	1.16e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—malignant glioma	1.16e-05	0.000124	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—malignant glioma	1.15e-05	0.000122	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—malignant glioma	1.13e-05	0.000121	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CAV1—malignant glioma	1.13e-05	0.00012	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—malignant glioma	1.13e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—malignant glioma	1.13e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—malignant glioma	1.12e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—malignant glioma	1.11e-05	0.000118	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—malignant glioma	1.09e-05	0.000116	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—malignant glioma	1.05e-05	0.000112	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	1.04e-05	0.00011	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.03e-05	0.00011	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—malignant glioma	1.03e-05	0.000109	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—malignant glioma	1.02e-05	0.000109	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—malignant glioma	1e-05	0.000107	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—malignant glioma	9.92e-06	0.000106	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—malignant glioma	9.8e-06	0.000104	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—malignant glioma	9.48e-06	0.000101	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	9.43e-06	0.0001	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—malignant glioma	9.21e-06	9.82e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—malignant glioma	9.12e-06	9.72e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—malignant glioma	9.04e-06	9.63e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—malignant glioma	8.6e-06	9.17e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—malignant glioma	8.46e-06	9.02e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—malignant glioma	7.88e-06	8.4e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—malignant glioma	7.81e-06	8.32e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—malignant glioma	7.7e-06	8.21e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—malignant glioma	6.81e-06	7.26e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—malignant glioma	4.8e-06	5.12e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—malignant glioma	3.92e-06	4.18e-05	CbGpPWpGaD
